GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Key takeaways: Less than 10% of adults receiving tirzepatide in clinical trials reported a serious adverse event. Gastrointestinal adverse events were common and increased with tirzepatide dosage.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Studies were included if they were clinical- or randomized controlled trials investigating the performance of Tirzepatide against insulin in any of the following outcomes – Body weight, fasting ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

A phase 3 clinical trial of tirzepatide, sold as Mounjaro, has demonstrated that if taken after an initial weight loss brought about by diet and lifestyle changes, the drug can lead to significant ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Weight-loss injections have been found less effective in real-life scenarios than in controlled lab settings, with usage patterns playing a significant role, according to new research. Semaglutide ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.